Race Oncology (ASX: RAC) Webcast Replay
9th November, 2022
Race Oncology (ASX: RAC) a company owning a “first-in-class and best-in-class” clinical-stage drug operating within a US$148 billion (2021) global industry.
As a part of our ‘The Insiders: Meet the CEOs’ series, Chief Scientific Officer Daniel Tillett, provides valuable insights to the company, its key markets and industry, and future prospects.
Recorded on 9th November 2022 at 12pm (AEDT).
Join the next The Insider: Meet the CEOs webcast
FEATURED SPEAKER
Daniel Tillett
Chief Scientific Officer - Race Oncology (ASX: RAC)
Race Oncology is a precision oncology company with a lead drug, Zantrene, capable of targeting a potential 15% of all cancers within the total estimated US$272 billion (by 2030) global cancer drug market. Aussie biotech investor Andrew Merchant (Merchant Funds) noted in October that the company had a balance sheet with ~$40 million in cash, skin-in-the-game and stock buyback factors and more. The company is led by a seasoned team and board supported by a network of key opinion leaders and collaborators, including Phillip Lynch, Dr John Cullity and Professor Borje Andersson. Race has also identified an independent US$10 billion market opportunity for Zantrene in preventing heart damage caused by chemotherapy.
